Acchrom Technologies

Explore the latest insights on Acchrom Technologies and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Technologies’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Deals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Atavistik Bio announced a strategic research collaboration with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to discover and develop novel small molecule therapies targeting multiple targets in cardiovascular, renal, and…

September 28, 2026

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

September 28, 2026

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

September 28, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals